{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-006125","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.363270+00:00","generated_at":"2026-06-18T11:51:23.238170+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rallybio reports FY2022 net loss of $66.7M; RLYB212 achieves proof-of-concept in Phase 1b","bullets":["Net loss for FY2022 was $66.7M ($2.09/share) vs $47.0M ($1.84/share) in 2021; Q4 loss $16.2M.","RLYB212 Phase 1b proof-of-concept: single dose eliminated >90% of HPA-1a positive platelets; well-tolerated.","Cash, equivalents, and marketable securities $169.0M as of Dec 31, 2022; runway into Q1 2025.","RLYB211 discontinued; RLYB212 multi-dose cohort initiated, data expected Q4 2023.","Jonathan Lieber appointed CFO effective Feb 1, 2023; follow-on offering raised ~$55M in Nov 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-006125","json":"https://secwatch.observer/filing/0000950170-23-006125.json","markdown":"https://secwatch.observer/filing/0000950170-23-006125.md","text":"https://secwatch.observer/filing/0000950170-23-006125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000095017023006125/0000950170-23-006125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000095017023006125/rlyb-20230306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:51:23.238170+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"73cf843ddb7be3f4a605a5a77b4064f4559a9a6d","claim":"Rallybio Corp reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On March 6, 2023, Rallybio Corporation issued a press release announcing its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739410/000095017023006125/0000950170-23-006125-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}